Home
Products

Recombinant Proteins
Bioactive Proteins Cytokines and Growth Factors Immune Checkpoint Proteins Enzyme Other Proteins

Antibodies
Primary antibodies Recombinant Monoclonal Antibodies Secondary antibodies Flow Cytometry (FACS) Antibodies Neutralizing Antibodies Isotype Controls Research Grade Biosimilars InVivo Plus InVivo Antibodies XtenNano®Nanobodies Bispecific Antibodies Antibodies against Small Molecules Tag Antibodies Anti-idiotype Antibodies

Assay Kits
ELISA Kits ADA Assay Kits PK Assay Kits Antibody Pairs
Research Area
Featured Products
Support
Information
- BioSpotlight
- Literature Highlights
About Us
Promotion Center

T cell cross-priming by PD-L1+ type 1 conventional dendritic cells mediates the antitumor efficacy of a PD-L1×4-1BB bispecific antibody

Immunity

Bispecific antibodies that conditionally engage costimulatory receptors aim to enhance antitumor T cell immunity while limiting systemic toxicity. Therapeutic efficacy of PD-L1×4-1BB was largely independent of PD-L1 expression on malignant cells but waned in Batf3-/- mice or upon depletion of type 1 conventional dendritic cells (cDC1s).

Related products

Catalog No.	Product Name	Description	Target
HV974296	Anti-Human PD-L1 Reference Antibody (GR1405	Anti-Human CD274/PD-L1/B7-H1 (GR1405) (HV974296) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.	B7 homolog 1, B7-H1, B7H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, Programmed death ligand 1

Recombinant Proteins

Antibodies

Assay Kits

T cell cross-priming by PD-L1+ type 1 conventional dendritic cells mediates the antitumor efficacy of a PD-L1×4-1BB bispecific antibody